{"id":"W2099988058","doi":"10.1186/1471-2407-11-313","title":"Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study","year":2011,"lang":"en","type":"article","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer; Amgen; American Heart Association","keywords":"Erlotinib; Gemcitabine; Medicine; Pharmacokinetics; Pharmacology; Nausea; Adverse effect; Internal medicine; Phases of clinical research; Oncology; Tolerability; Epidermal growth factor receptor; Gastroenterology; Toxicity; Chemotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001639612,0.001221257,0.001777299,0.0003870842,0.000416372,0.000807888,0.000772146,0.001059526,0.002413601],"category_scores_gemma":[0.0009188955,0.0006183072,0.001073601,0.0003901524,0.0006577094,0.0006894338,0.0002901647,0.002937831,0.0007990238],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00112105,"about_ca_system_score_gemma":0.001613515,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005236946,"about_ca_topic_score_gemma":0.001437803,"domain_scores_codex":[0.9995099,0.0002263716,0.00002914765,0.00008031623,0.00008581542,0.00006843779],"domain_scores_gemma":[0.9992187,0.0001055273,0.0002617866,0.00004862739,0.00006227003,0.000302972],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.42595,0.1342475,0.01842981,0.001765017,0.002387597,0.0006060881,0.0004591741,0.006755684,0.1971541,0.0002925955,0.007691238,0.2042612],"study_design_scores_gemma":[0.3117635,0.6241249,0.03593587,0.00008546573,0.0007653106,0.00118443,0.00006233277,0.003385691,0.01568635,0.0001698532,0.00676794,0.00006833842],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941606,0.002784015,0.0004860709,0.000354716,0.00005660008,0.0008445691,0.000475847,0.00006515052,0.000772358],"genre_scores_gemma":[0.9914082,0.002097659,0.001574875,0.000659471,0.0001109524,0.001064006,0.00194381,0.00003891907,0.00110204],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002413601,"threshold_uncertainty_score":0.008671224,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1121455682981794,"score_gpt":0.4283166535785267,"score_spread":0.3161710852803472,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}